Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab (AK112) plus chemotherapy as neoadjuvant therapy for locally advanced oral squamous cell carcinoma
ChiCTR2600117076Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Jan 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ivonescimab in Oral Mucosal Carcinoma, sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: Major Pathological Response (MPR) Rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on ChiCTR2600117076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117076.